Trial Number
217-21
Conditions
Pediatric Cancer, Lymphoma
Participant Age Range
up to 2 Years
Participant Gender
Any
Enrolling Participants
Yes
Overview
“A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma”
A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma.